Comparison of dose-dense ABVD and standard ABVD in the treatment of early unfavorable and advanced Hodgkin's lymphoma: a retrospective analysis.
10.1007/s11596-014-1268-2
- Author:
Yun-xia TAO
1
;
San-yuan SUN
;
Su-yi KANG
;
Li-qiang ZHOU
;
Yuan-kai SHI
;
Ye-xiong LI
;
Yan SUN
Author Information
1. Department of Medical Oncology, Central Hospital of Xuzhou, Xuzhou, 221009, China, tyx876@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Antineoplastic Combined Chemotherapy Protocols;
administration & dosage;
Bleomycin;
administration & dosage;
Combined Modality Therapy;
methods;
Dacarbazine;
administration & dosage;
Disease-Free Survival;
Dose-Response Relationship, Drug;
Doxorubicin;
administration & dosage;
Female;
Hodgkin Disease;
drug therapy;
pathology;
Humans;
Male;
Middle Aged;
Neoplasm Staging;
Prednisone;
Retrospective Studies;
Vinblastine;
administration & dosage
- From:
Journal of Huazhong University of Science and Technology (Medical Sciences)
2014;34(2):260-264
- CountryChina
- Language:English
-
Abstract:
This retrospective analysis compared standard regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with the dose-dense ABVD regimen (ABVD-21) in terms of efficacy and toxicity. Patients who had early-stage unfavorable or advanced Hodgkin's lymphoma (HL) according to German Hodgkin Study Group criteria from March 1999 to February 2011 were analyzed for treatment response, long-term survival and hematological toxicity. There were 85 patients in the ABVD-21 group and 118 patients in the ABVD group respectively. The complete remission rates after completion of treatment were 92.9% and 90.7% for ABVD-21 and ABVD, respectively. During a median follow-up period of 62 months, no significant difference was found in projected 10-year progression-free survival (PFS) and overall survival (OS) rates (84.7% and 94.1% respectively for ABVD-21; 81.4% and 91.5% for ABVD). Subgroup analyses showed that ABVD-21 was significantly better than ABVD for patients with IPS≥3 in terms of PFS and OS rates. Grade 3 to 4 leukopenia (51.8% vs. 28.8%, P=0.001) and neutropenia (57.6% vs. 39.0%, P=0.009) were more common with ABVD-21. We were led to conclude that dose-dense ABVD did not result in better tumor control and overall survival than did ABVD for early-stage unfavorable HL. However, patients at high risk, for example, with IPS≥3, may benefit from dose-dense ABVD.
